血管生成素-2 作为骨肉瘤预后生物标志物的价值：系统评价和荟萃分析方案。
The value of Angipoietin-2 as a biomarker for the prognosis of osteosarcoma: A protocol for systematic review and meta-analysis.
机构信息
Department of Traumatic Surgery, The Second Affiliated Hospital of Hainan Medical College, Haikou, Hainan Province, China.
Department of Orthopaedic, The Second Affiliated Hospital of Hainan Medical College, Haikou, Hainan Province, China.
出版信息
Medicine (Baltimore). 2021 Aug 13;100(32):e26923. doi: 10.1097/MD.0000000000026923.
BACKGROUND
The function of Angipoietin-2 (Agn2) in osteosarcoma has not been fully explored and exists controversial. Therefore, we conducted a meta-analysis to investigate the role of Agn2 in the prognosis of osteosarcoma. In addition, bioinformatics analysis was carried out to reveal the mechanism and related pathways of Agn2 in osteosarcoma.
METHODS
Literature search was operated on databases up to July 2021, including PubMed, Web of Science, China National Knowledge Infrastructure, China Biology Medicine disc, and Wan Fang Data. The relation between Agn2 expression and survival outcome was estimated by hazard ratio and 95% confidence interval. Meta-analysis was performed on the Stata 16.0. Being obtained from The Cancer Genome Atlas, the original data were used to further verify the prognostic role of Agn2 in osteosarcoma. Gene set enrichment analysis was applied to predict the potential mechanism of Agn2. The correlation between Agn2 and osteosarcoma immune infiltration was analyzed by TIMER database.
RESULTS
The results of this meta-analysis would be submitted to peer-reviewed journals for publication.
CONCLUSION
This study will provide evidence for the exploration of the relationship between Agn2 and the prognosis of osteosarcoma and its mechanism.
ETHICS AND DISSEMINATION
The private information from individuals will not be published. This systematic review also should not damage participants' rights. Ethical approval is not available. The results will be published in a peer-reviewed journal or disseminated in relevant conferences.
OSF REGISTRATION NUMBER
DOI 10.17605/OSF.IO/GWQ53.
背景
血管生成素 2（Agn2）在骨肉瘤中的作用尚未完全阐明，存在争议。因此，我们进行了一项荟萃分析，以研究 Agn2 在骨肉瘤预后中的作用。此外，还进行了生物信息学分析，以揭示 Agn2 在骨肉瘤中的作用机制和相关途径。
方法
截至 2021 年 7 月，我们在 PubMed、Web of Science、中国知网、中国生物医学文献数据库和万方数据等数据库中进行了文献检索。使用风险比和 95%置信区间评估 Agn2 表达与生存结局之间的关系。使用 Stata 16.0 进行荟萃分析。从 The Cancer Genome Atlas 获得原始数据，进一步验证 Agn2 在骨肉瘤中的预后作用。应用基因集富集分析预测 Agn2 的潜在作用机制。通过 TIMER 数据库分析 Agn2 与骨肉瘤免疫浸润的相关性。
结果
这项荟萃分析的结果将提交给同行评议期刊发表。
结论
本研究将为探索 Agn2 与骨肉瘤预后的关系及其机制提供依据。
伦理和传播
不会公布个人的隐私信息。本系统评价也不应损害参与者的权利。不需要伦理批准。研究结果将发表在同行评议的期刊上或在相关会议上传播。
OSF 注册号：DOI 10.17605/OSF.IO/GWQ53。
Zotero 插件